Patents by Inventor Sean E. Mcguire

Sean E. Mcguire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10082510
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 25, 2018
    Assignee: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Subhamoy Dasgupta, Nicholas Mitsiades, Arun Sreekumar, Sean E. Mcguire
  • Publication number: 20170067903
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.
    Type: Application
    Filed: May 5, 2015
    Publication date: March 9, 2017
    Applicant: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Subhamoy Dasgupta, Nicholas Mitsiades, Arun Sreekumar, Sean E. Mcguire
  • Publication number: 20090269753
    Abstract: Osteoporosis is a common skeletal disease characterized by loss of bone mineral density (BMD) and increased risk of fracture. Osteoporosis most commonly occurs in postmenopausal women due to estrogen deficiency. We identified 3 genetic variants in steroid receptor coactivator 1 (SRC-1) that are significantly associated with a decrease in BMD in women. We characterized a functional variant in exon 18 of SRC-1 that is associated with increased loss of bone mineral density in women who received tamoxifen for treatment or prevention of breast cancer. In vitro experiments show that this variant decreases estrogen receptor alpha response (ER-alpha) to hormone, suggesting an attenuated response to endogenous and exogenous hormones in the bone of these women, and therefore a need for additional bone protective measures.
    Type: Application
    Filed: November 20, 2008
    Publication date: October 29, 2009
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Steffi Oesterreich, Alexandra Richter, Adrian Lee, C. Kent Osborne, Sean E. Mcguire, Ryan Hartmaier